An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half in four people taking the highest dose, raising ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

CRISPR Therapeutics (CRSP) on Saturday announced new results from a Phase 1 trial for CTX310, an in vivo gene editing therapy ...

A CRISPR-based gene editing therapy dramatically reduced levels of LDL cholesterol and triglycerides in patients with heart ...

People who have tried medication to lower their dangerously high levels of cholesterol and other blood fats – without success ...

Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...